Kerala State Drug Formulary.pdf

Dermatological Drugs
National Leprosy Eradication program Classification
1. Tuberculoid (TT) : Well defined hypopigmented anaesthetic macules
and plaques with loss of hair and hypohidrosis. The lesions have dry
surface.
2. Borderline Tuberculoid (BT): Hypopigmented anaesthetic macules and
plaques with party well defined and partly ill defined borders. Satellite
lesions present.
3. Borderline Borderline (BB): Multiple lesions. Annular, geographic,
punched out and inverted saucer lesions present. Multiple nerve
thickening present.
4. Borderline Lepromatous (BL): Multiple generalized asymmetric
macules, papules and nodules. Bilateral asymmetrical nerve
thickening. Smear positive.
5. Lepromatous (LL): Multiple generalized symmetric macules, papules
and nodules. Leonine facies present. Bilateral symmetrical nerve
thickening present. Smear positive
6. Indeterminate (IL): Single or multiple macules. No raised lesions.
7. Pure neuritic leprosy (PL): No skin lesions. Only nerve thickening.
Dapsone
I: Leprosy, Dermatitis herpetiformis, chloroquine resistant
malaria, pneumocystis pneumonia in AIDs.
C/I: Sulphone allergy, severe G6PD deficiency, severe
anaemia, porphyria.
P/C: Mild to moderate G6PD deficiency, sulphonamide
allergy, moderate anaemia, cardiac and pulmonary
disease, lactation and pregnancy.
A/E: Hemolytic anaemia, methemoglobnemia, hepatitis,
dapsone syndrome, rash, fixed drug eruption,
psychosis, motor neuropathy, Stevens Johnson
syndrome.
P/A: Tablet 50 mg, 100 mg
Dose: Paucibacillary leprosy: 100 mg daily self administered
for 6 months
Multibacillary leprosy: 100 mg daily self administered
for 1 year
Cost: Tab 50 mg (1000): Rs. 40 – 42/-
196